MX2021006731A - Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico. - Google Patents
Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico.Info
- Publication number
- MX2021006731A MX2021006731A MX2021006731A MX2021006731A MX2021006731A MX 2021006731 A MX2021006731 A MX 2021006731A MX 2021006731 A MX2021006731 A MX 2021006731A MX 2021006731 A MX2021006731 A MX 2021006731A MX 2021006731 A MX2021006731 A MX 2021006731A
- Authority
- MX
- Mexico
- Prior art keywords
- atp
- protein kinase
- kinase inhibitors
- activated protein
- catalytic site
- Prior art date
Links
- 230000003197 catalytic effect Effects 0.000 title 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 title 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 title 1
- 101100291385 Drosophila melanogaster p38a gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776837P | 2018-12-07 | 2018-12-07 | |
| PCT/US2019/064960 WO2020118194A1 (en) | 2018-12-07 | 2019-12-06 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021006731A true MX2021006731A (es) | 2021-09-23 |
Family
ID=70974384
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006731A MX2021006731A (es) | 2018-12-07 | 2019-12-06 | Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico. |
| MX2024004162A MX2024004162A (es) | 2018-12-07 | 2021-06-07 | Inhibidores de proteinas quinasas activadas por mitogeno p38 en sitio no atp/catalitico. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004162A MX2024004162A (es) | 2018-12-07 | 2021-06-07 | Inhibidores de proteinas quinasas activadas por mitogeno p38 en sitio no atp/catalitico. |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11078171B2 (enExample) |
| EP (2) | EP3890733B1 (enExample) |
| JP (2) | JP7594787B2 (enExample) |
| CN (1) | CN113395963B (enExample) |
| AU (3) | AU2019392904B9 (enExample) |
| CA (1) | CA3122371A1 (enExample) |
| ES (1) | ES3025468T3 (enExample) |
| IL (1) | IL283755B1 (enExample) |
| MX (2) | MX2021006731A (enExample) |
| WO (1) | WO2020118194A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109640970B (zh) | 2016-06-23 | 2023-05-23 | 马里兰大学巴尔的摩分校 | 选择性p38α特异性MAPK抑制剂 |
| MX2021006731A (es) * | 2018-12-07 | 2021-09-23 | Univ Maryland | Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico. |
| IL293965A (en) | 2019-12-19 | 2022-08-01 | Janssen Pharmaceutica Nv | History of Spiro straight chain transformed |
| JP7495526B2 (ja) | 2020-05-18 | 2024-06-04 | ジーニー ライフサイエンシズ インコーポレイテッド | Ｐ３８アルファマイトジェン活性化プロテインキナーゼ阻害剤 |
| JP2023546835A (ja) | 2020-10-29 | 2023-11-08 | ジーニー ライフサイエンシズ インコーポレイテッド | 結晶性５－（ジメチルアミノ）－ｎ－（４－（モルホリノメチル）フェニル）ナフタレン－１－スルホンアミド二塩酸塩二水和物 |
| US12378229B2 (en) | 2021-02-02 | 2025-08-05 | Liminal Biosciences Limited | GPR84 antagonists and uses thereof |
| IL306101A (en) * | 2021-03-23 | 2023-11-01 | Gen1E Lifesciences Inc | Naphthyl-mutated p38 alpha mitogen-activated protein kinase inhibitors |
| UY39681A (es) | 2021-03-26 | 2022-10-31 | Novartis Ag | Derivados de ciclobutilo 1,3–sustituidos y sus usos |
| US12404242B2 (en) | 2021-12-17 | 2025-09-02 | Reglagene, Inc. | Compositions and methods for making and using small molecules in the treatment of cancer |
| IL321433A (en) | 2022-12-16 | 2025-08-01 | Astrazeneca Ab | Purines 2,6,9 trimethylated |
| US12215102B2 (en) | 2023-02-28 | 2025-02-04 | Reglagene, Inc. | Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions |
| CN116621794B (zh) * | 2023-05-22 | 2025-03-11 | 上海大学 | 一种5-苄基-2-氨基-1,3-噻唑类衍生物及其合成方法与应用 |
| US12116353B1 (en) * | 2024-04-25 | 2024-10-15 | Genie Lifesciences Inc. | Crystalline chloro-n-(4-(morpholinomethyl)phenyl)benzamide and crystalline hydrochloride salt |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR96352E (fr) | 1967-12-29 | 1972-06-16 | Science Union & Cie | Nouveaux dérives du spiro (4,5) decane et leur procédé de préparation. |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| DE19801646A1 (de) | 1998-01-17 | 1999-07-22 | Bayer Ag | Substituierte alpha,beta-annellierte Butyrolactone |
| JPH11269146A (ja) | 1998-03-24 | 1999-10-05 | Mitsui Chem Inc | 分化誘導剤 |
| PL350998A1 (en) | 1999-03-24 | 2003-02-24 | Anormed Inc | Chemokine recpetor binding heterocyclic compounds |
| EP2194058B1 (en) * | 2002-09-04 | 2013-11-27 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidines suitable for the treatment of cancer diseases |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| HRP20050711A2 (en) | 2003-02-13 | 2006-09-30 | Sanofi-Aventis Deutschland Gmbh | NITROGEN-SUBSTITUTED HEXAHYDROPYRAZINO[1,2-a]PYRIMIDINE-4,7-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS |
| US7297817B2 (en) | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
| US20070208015A1 (en) * | 2004-04-13 | 2007-09-06 | Astex Therapeutics, Ltd. | 5-Morpholinylmethylthiophenyl Pharmaceutical Compounds As P38 MAP Kinase Modulators |
| US7829560B2 (en) * | 2004-07-08 | 2010-11-09 | Arqule, Inc. | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase |
| WO2006105237A2 (en) | 2005-03-29 | 2006-10-05 | The University Of Maryland, Baltimore | Inhibitors for extracellular signal-regulated kinase docking domains and uses therefor |
| US7915245B2 (en) * | 2007-02-01 | 2011-03-29 | The Board Of Regents Of The University Of Texas System | Methods and compositions of trail-death receptor agonists/activators |
| TW200904421A (en) | 2007-05-03 | 2009-02-01 | Astellas Pharma Inc | New compounds |
| WO2009106844A1 (en) * | 2008-02-29 | 2009-09-03 | Chroma Therapeutics Ltd. | Inhibitors of p38 map kinase |
| US20120172375A1 (en) | 2008-11-07 | 2012-07-05 | Bruce Trapp | Compounds and methods of promoting oligodendrocyte precursor differentiation |
| WO2010082912A1 (en) | 2009-01-15 | 2010-07-22 | Avalon Pharmaceuticals | Derivatives of multi-ring aromatic compounds and uses as anti-tumor agents |
| WO2010094977A1 (en) | 2009-02-23 | 2010-08-26 | Arrow Therapeutics Limited | Novel biphenyl compounds useful for the treatment of hepatitis c |
| CN108451955B (zh) * | 2011-05-03 | 2022-02-01 | 安吉奥斯医药品有限公司 | 用于治疗的丙酮酸激酶活化剂 |
| HK1217687A1 (zh) | 2013-01-15 | 2017-01-20 | Karl Alex MÜLLER | 利用紫外线辐射的氧化物的快速固态反应 |
| DK2981535T3 (da) | 2013-04-02 | 2021-03-01 | Oxular Acquisitions Ltd | Urinstofderivater, der er anvendelige som kinaseinhibitorer |
| US9025712B2 (en) | 2013-07-30 | 2015-05-05 | Pixart Imaging Inc. | Sensor, clock frequency adjusting system and method thereof |
| US10328080B2 (en) * | 2013-12-05 | 2019-06-25 | Acerta Pharma, B.V. | Therapeutic combination of PI3K inhibitor and a BTK inhibitor |
| TWI664967B (zh) | 2014-02-14 | 2019-07-11 | 英商瑞斯比維特有限公司 | 新穎化合物（一） |
| EP3119397B1 (en) * | 2014-03-19 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| GB201417168D0 (en) | 2014-09-29 | 2014-11-12 | Univ Hertfordshire Higher Education Corp | Compounds |
| MA40775A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
| WO2016073633A1 (en) | 2014-11-05 | 2016-05-12 | University Of Kansas | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) |
| WO2017011323A1 (en) * | 2015-07-10 | 2017-01-19 | University Of Maryland, Baltimore | Small molecule inhibitors of the mcl-1 oncoprotein and uses thereof |
| CN109640970B (zh) * | 2016-06-23 | 2023-05-23 | 马里兰大学巴尔的摩分校 | 选择性p38α特异性MAPK抑制剂 |
| WO2018085348A1 (en) * | 2016-11-03 | 2018-05-11 | Actavalon, Inc. | Substituted quinolines and methods for treating cancer |
| TW201829381A (zh) | 2016-12-22 | 2018-08-16 | 美商拜奧馬林製藥公司 | 組蛋白脫乙醯基酶抑制劑 |
| US11040945B2 (en) | 2017-12-06 | 2021-06-22 | Lin Bioscience Pty Ltd. | Tubulin inhibitors |
| MX2021006731A (es) * | 2018-12-07 | 2021-09-23 | Univ Maryland | Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico. |
| US20230140941A1 (en) | 2020-03-13 | 2023-05-11 | University Of Maryland, Baltimore | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
| JP7495526B2 (ja) | 2020-05-18 | 2024-06-04 | ジーニー ライフサイエンシズ インコーポレイテッド | Ｐ３８アルファマイトジェン活性化プロテインキナーゼ阻害剤 |
| IL306101A (en) | 2021-03-23 | 2023-11-01 | Gen1E Lifesciences Inc | Naphthyl-mutated p38 alpha mitogen-activated protein kinase inhibitors |
-
2019
- 2019-12-06 MX MX2021006731A patent/MX2021006731A/es unknown
- 2019-12-06 AU AU2019392904A patent/AU2019392904B9/en active Active
- 2019-12-06 JP JP2021532311A patent/JP7594787B2/ja active Active
- 2019-12-06 CN CN201980091398.5A patent/CN113395963B/zh active Active
- 2019-12-06 ES ES19893204T patent/ES3025468T3/es active Active
- 2019-12-06 WO PCT/US2019/064960 patent/WO2020118194A1/en not_active Ceased
- 2019-12-06 EP EP19893204.8A patent/EP3890733B1/en active Active
- 2019-12-06 EP EP25161840.1A patent/EP4606792A1/en active Pending
- 2019-12-06 CA CA3122371A patent/CA3122371A1/en active Pending
-
2020
- 2020-05-11 US US16/872,114 patent/US11078171B2/en active Active
-
2021
- 2021-06-06 IL IL283755A patent/IL283755B1/en unknown
- 2021-06-07 MX MX2024004162A patent/MX2024004162A/es unknown
- 2021-06-16 US US17/349,468 patent/US11718595B2/en active Active
-
2022
- 2022-11-04 AU AU2022263608A patent/AU2022263608B2/en active Active
-
2023
- 2023-04-26 JP JP2023072147A patent/JP2023106403A/ja active Pending
- 2023-06-07 US US18/206,925 patent/US12202810B2/en active Active
-
2024
- 2024-05-22 AU AU2024203398A patent/AU2024203398A1/en active Pending
- 2024-12-05 US US18/970,196 patent/US20250100985A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11718595B2 (en) | 2023-08-08 |
| EP4606792A1 (en) | 2025-08-27 |
| EP3890733A4 (en) | 2022-05-04 |
| NZ777458A (en) | 2024-03-22 |
| US20230312498A1 (en) | 2023-10-05 |
| EP3890733B1 (en) | 2025-04-16 |
| IL283755A (en) | 2021-07-29 |
| WO2020118194A1 (en) | 2020-06-11 |
| AU2019392904A9 (en) | 2022-08-04 |
| US11078171B2 (en) | 2021-08-03 |
| JP2022511555A (ja) | 2022-01-31 |
| US12202810B2 (en) | 2025-01-21 |
| US20200331874A1 (en) | 2020-10-22 |
| EP3890733A1 (en) | 2021-10-13 |
| US20210317097A1 (en) | 2021-10-14 |
| AU2022263608A1 (en) | 2022-12-15 |
| CN113395963A (zh) | 2021-09-14 |
| AU2019392904B9 (en) | 2022-12-22 |
| AU2022263608B2 (en) | 2024-02-29 |
| AU2019392904B2 (en) | 2022-08-25 |
| IL283755B1 (en) | 2025-12-01 |
| CN113395963B (zh) | 2024-06-25 |
| EP3890733C0 (en) | 2025-04-16 |
| US20250100985A1 (en) | 2025-03-27 |
| AU2019392904A1 (en) | 2021-07-15 |
| JP7594787B2 (ja) | 2024-12-05 |
| MX2024004162A (es) | 2024-04-23 |
| JP2023106403A (ja) | 2023-08-01 |
| ES3025468T3 (en) | 2025-06-09 |
| CA3122371A1 (en) | 2020-06-11 |
| AU2024203398A1 (en) | 2024-06-06 |
| AU2019392904A2 (en) | 2021-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006731A (es) | Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico. | |
| EA202092590A1 (ru) | Пиридазиноны в качестве ингибиторов parp7 | |
| EA201992781A1 (ru) | Ингибиторы g12c kras и способы их применения | |
| MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| MX2020006128A (es) | Inhibidores de la proteina de activacion de fibroblastos. | |
| MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| MY203971A (en) | Anti-lag-3 antibodies and compositions | |
| ZA202204284B (en) | Inhibitors of raf kinases | |
| EA202092000A1 (ru) | Ингибиторы димеризации egfr и их использование | |
| PH12020551728A1 (en) | Stat3 inhibitors | |
| EA201691114A1 (ru) | Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии | |
| EA201690708A1 (ru) | Ингибиторы erk и способы применения | |
| MY195443A (en) | Tissue Factor Pathway Inhibitor Antibodies and uses Thereof | |
| MX2023004314A (es) | Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos. | |
| SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز | |
| MX2020011344A (es) | Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios. | |
| MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| EP4616910A3 (en) | Pcna inhibitors | |
| MX390435B (es) | Inhibidor selectivo de receptor de factor de crecimiento epidermico mutante de insercion de exon 20. | |
| EA201892287A1 (ru) | Фармацевтические комбинации для лечения рака | |
| AU2018284249A1 (en) | Aminothiazole compounds as protein kinase inhibitors | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| WO2016198698A8 (en) | P38 inhibitors for the treatment and prophylaxis of liver cancer |